Frank Stappenbeck
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$5.7MFederal grants as PI7 awards
2Patents grantedLatest Dec 22, 2020
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
7 awards · $5.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| May 10, 2019 | NIH | SBIR Phase II Preclinical Development of Oxy200 for the Treatment of Osteoporosis | $975K | Max Biopharma, Inc. |
| Sep 30, 2018 | NIH | SBIR Phase II Preclinical Development of Oxy200 for the Treatment of Osteoporosis | $2.0M | Max Biopharma, Inc. |
| May 31, 2017 | NIH | SBIR Phase II Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analogues | $500K | Max Biopharma, Inc. |
| Feb 27, 2017 | NIH | SBIR Phase II Synthesis of bone-selective osteogenic oxysterols | $451K | Max Biopharma, Inc. |
| Sep 14, 2016 | NIH | SBIR Phase II Design and synthesis of bone-selective osteogenic oxysterol-bisphosphonate analogues | $499K | Max Biopharma, Inc. |
| Mar 17, 2016 | NIH | SBIR Phase II Synthesis of bone selective osteogenic oxysterols | $899K | Max Biopharma, Inc. |
| Mar 16, 2016 | NIH | SBIR Phase II Synthesis of bone-selective osteogenic oxysterols | $449K | Max Biopharma, Inc. |
3 patents as inventor
- US 10869875Max Biopharma, Inc.Dec 22, 2020
- US 9637514Max Biopharma, Inc.May 2, 2017
- US Max Biopharma, Inc.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#211
Awards as PI#250
Patents#102
Companies
- Max Biopharma, Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.